Weight-loss medicines have become a major force in healthcare, revolutionizing the treatment of obesity and expanding into new areas such as sleep apnea and heart disease. After years of ineffective diets and social stigma, GLP-1s like Ozempic, Wegovy, Mounjaro, and Zepbound gained widespread acceptance, generating billions for pharmaceutical companies. This shift has sparked a fierce competition to study the drugs for additional conditions, including heart disease and alcoholism, marking a significant turning point in the fight against obesity.
Source: https://www.bloomberg.com/news/features/2024-12-26/ozempic-zepbound-wegovy-mounjaro-weight-loss-shots-big-year